Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-90014496 in B-cell Non-Hodgkin Lymphoma
NCT05421663Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2022
- Primary completion
- Jul 2041
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 8
01
Overview
A Phase 2 trial of prizloncabtagene autoleucel in B-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma (DLBCL), sponsored by Janssen Pharmaceutical. Started Aug 2022; status: active, not recruiting.
02
Drugs
prizloncabtagene autoleucel
03
Conditions
B-cell non-Hodgkin lymphomadiffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05421663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05421663.